Contract research, development and manufacturing organisation (CDMO) Curia on Thursday announced progress on the expansion at its sterile drug product facility in Glasgow, Scotland, as well as enhancements to its proprietary platform for cell line development.

The Glasgow site has 25 years of experience in formulation, lyophilisation development and sterile fill-finish capabilities, including ADCs and other highly potent products.

Expected to be completed by early 2027, the expansion will add an Annex 1 compliant isolator-based vial filling line and lyophiliser. The company says that once complete, Glasgow will be able to fill batches up to 20,000 vials, and will be well-positioned to support future small-scale commercial fills.

Curia's clinical drug substance development capabilities have also been enhanced with improvements to the company's cell line development (CLD) platform. The CLD offering at its Hopkinton, MA facility has been enhanced to incorporate IP-free semi-targeted integration technology that results in 6-fold higher titers compared to random integration technology. Curia's stable platform, CHO-GSN, was derived from the same parental cell line as its transient platform, TunaCHO, allowing partners to efficiently scale-up from discovery to GMP.